Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Correction: Calcium electroporation for treatment of sarcoma in preclinical studies

    Research output: Contribution to journalJournal articleResearch

  2. Expression and function of Kv1.3 channel in malignant T cells in Sézary syndrome

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Real-world evidence to guide healthcare policies in oncology

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Lynch syndrome-associated epithelial ovarian cancer and its immunological profile

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Midkine-A potential therapeutic target in melanoma

    Research output: Contribution to journalComment/debateResearchpeer-review

  3. Metastatic melanoma presenting with subacute sensory neuronopathy

    Research output: Contribution to journalLetterResearchpeer-review

View graph of relations

Immune therapy is a promising field within oncology but has been unsuccessful in ovarian cancer (OC). Still, there is rationale and evidence supporting immune therapy in OC. We investigated the potential for adoptive cell therapy (ACT) from in vitro expanded tumor-infiltrating lymphocytes (TILs) in combination with checkpoint inhibitors (ICI) and conducted immunological testing of ex vivo expanded TILs (REP-TILs). Six patients with late-stage metastatic high-grade serous OC were treated with immune therapy consisting of ipilimumab followed by surgery to obtain TILs and infusion of REP-TILs, low-dose IL-2 and nivolumab. One patient achieved a partial response and 5 others experienced disease stabilization for up to 12 months. Analysis of the REP-TILs with flow- and mass-cytometry show primarily activated and differentiated effector memory T cells. REP-TILs showed in vitro reactivity and expression of inhibitory receptors, such as LAG-3 and PD-1. Furthermore, our data indicate that addition of ipilimumab therapy improves the T cell fold expansion during production, increase the level of CD8 T cell tumor reactivity, and favorably affect the T cell phenotype. We show that the combination of ICI and ACT is feasible and safe. With one partial response and one long-lasting SD, we demonstrated the potential of ACT in OC.

Original languageEnglish
JournalOncotarget
Volume11
Issue number22
Pages (from-to)2092-2105
Number of pages14
ISSN1949-2553
DOIs
Publication statusPublished - 2 Jun 2020

ID: 61244004